BioXcel Therapeutics (BTAI) Interest Coverage Ratio Growth (3y) (2022 - 2026)
Powered by 
Analysis
BioXcel Therapeutics (BTAI) Interest Coverage Ratio Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | 13.52% |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | -98.43% |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | 29.79% |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | 44.22% |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 33.30% |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | - |
| 10 | BioXcel Therapeutics | 2.19 Mn | 2.19 Mn | 160,000.00 | 47.00% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47.00% |
| Mar 31, 2026 | 45.69% |
| Dec 31, 2025 | 49.46% |
| Sep 30, 2025 | 32.41% |
| Jun 30, 2025 | 45.25% |
| Mar 31, 2025 | 91.75% |
| Dec 31, 2024 | 91.58% |
| Sep 30, 2024 | 88.17% |
| Jun 30, 2024 | 86.06% |
| Mar 31, 2024 | 87.89% |
| Dec 31, 2023 | 89.69% |
| Sep 30, 2023 | 85.58% |
| Jun 30, 2023 | 79.20% |
| Mar 31, 2023 | 81.74% |
| Dec 31, 2022 | -27.20% |
| Sep 30, 2022 | 72.51% |